This early-phase study is testing a special PET imaging agent called [89Zr]Zr-DFO-emapalumab to see if it can detect non-small cell lung cancer lesions and show how well the cancer responds to immunotherapy. Six adults with newly diagnosed lung cancer will receive the imaging age…
Phase: PHASE1 • Sponsor: Nerissa T. Viola • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC